Revelation Biosciences, Inc. (REVB) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

+2518.1%

$106.03

vs $4.05 price

Levered DCF

$112.23

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

-7.62

Distress zone

Rating

B-

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	-0.13×	-1.01×	-342.93×	-3.97×	-33.6×	-74.77×	-97,600×
P/B	0.22×	3.22×	6.2×	40.78×	-4,051.86×	1.81×	-97,172.9×
P/S	0×	0×	0×	0×	0×	0×	0×
EV / EBITDA	0.88×	-1.09×	-3.38×	-3.48×	-33.67×	0×	-97,172.9×
Gross margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Current ratio	5.41×	3.43×	2.18×	1.21×	0.89×	0.19×	0×
Debt / equity	0.08×	0×	0×	0×	-0.17×	0×	0×
Interest coverage	0×	0×	0×	0×	-286.18×	0×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	-100.6%	-319.4%	-1.8%	-1029.0%	12050.7%	-2.4%	100.0%
Return on invested capital	-94.4%	-169.4%	-130.2%	-1046.3%	14447.3%	-5.4%	100.0%
Return on assets	-77.0%	-227.1%	-1.0%	-196.8%	-587.0%	-2.2%	-16.0%
Free cash flow yield	-416.3%	-120.8%	-17.7%	-26.1%	-2.8%	-0.2%	0.0%
Earnings yield	-448.7%	-99.1%	-0.3%	-25.2%	-3.0%	-1.3%	-0.0%
Enterprise value	-$8M	$8.7M	$29.2M	$37.7M	$401.8M	$122.9M	$353.5M
Net debt / EBITDA	1.1×	0.82×	1.39×	0.48×	0.11×	0×	0×
Cash conversion cycle (days)	-7,790	-10,243	-19,816	-5,056	0	0	0